What is the clinical evidence from this study?

Study design: Other. Population: pulmonary hypertension. Intervention: Sotatercept. Primary outcome: Right Ventricular End-Diastolic Volume (RVEDV) (null, 95% CI null, p=null).

What does this research mean for the field?

Sotatercept shows promise for reversing RV remodeling and improving fibrosis in patients with pulmonary hypertension. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This review aims to explore the connection between right ventricular (RV) fibrosis and RV function in patients with pulmonary hypertension (PH).

January 9, 2026Open Access

Right Ventricular Fibrosis With Pulmonary Arterial Hypertension

Key Result

Sotatercept shows promise for reversing RV remodeling and improving fibrosis.

Key Points

This review aims to explore the connection between right ventricular (RV) fibrosis and RV function in patients with pulmonary hypertension (PH).
Examines structural and functional changes in the pulmonary vasculature related to PH.
Evaluates techniques for quantifying RV fibrosis.
Discusses clinical relevance and potential therapeutic strategies for improving right heart function.
RV fibrosis initially protects against RV dilatation but eventually leads to impaired cardiac function.
Excessive fibrosis correlates with the progression of right heart failure in PH patients.
Identifying quantification techniques may improve patient management and treatment outcomes.

PICO

Population

pulmonary hypertension

Intervention / Comparator

Sotatercept

Primary Outcome

Right Ventricular End-Diastolic Volume (RVEDV) — null (null), p=null

Main Result

Effect estimate: null (95% CI null)

p-value: p=null

Abstract

Pulmonary hypertension (PH) is a progressive disease caused by structural and functional changes in the pulmonary vasculature resulting from diverse etiologies. PH ultimately leads to increased right ventricular (RV) afterload, RV hypertrophy, fibrosis, and right heart failure (RHF). Moreover, RV fibrosis initially serves as a protective mechanism against pressure overload-induced RV dilatation, but eventually progresses to excessive fibrosis, which impairs cardiac function. This review explores the relationship between RV fibrosis and RV function in PH patients, examines the clinical relevance of this relationship, evaluates techniques for quantifying RV fibrosis, and presents potential therapeutic strategies aimed at preserving right heart function in PH patients.

Mark Helpful

Bookmark

Relay

View Full Paper